GET DAILY SIGNALSOneMedNet (ONMD) Shares Decline -31% in 30 Days After Reverse Split
Key Takeaways
- OneMedNet (ONMD) shares declined roughly 31% over the trailing 30 days, falling from about $6.33 to approximately $4.39.
- The move followed a 1-for-10 reverse stock split completed in late September 2026, a step commonly used to address exchange minimum-bid-price listing requirements.
- Selling pressure continued despite a run of commercial announcements, including a seven-figure multiyear data agreement and several new channel partnerships.
- On a trailing-quarter basis, the stock has extended a broader multi-month downtrend from levels near $7 in early-to-mid July.
- OneMedNet remains a thinly traded micro-cap with ongoing net losses and limited analyst coverage, factors that can amplify price volatility.
- For additional detail on this ticker, investors can review Price Targets, Earnings, and Forecast data across Tickeron's dedicated pages.
- Readers can also explore Trending AI Robots to see curated, top-performing AI trading bots.
OneMedNet's Business and Market Focus
OneMedNet Corporation operates as a healthcare software provider specializing in digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East. Its main platform, iRWD, supplies regulatory-grade imaging and clinical data to pharmaceutical firms, medical device makers, contract research organizations, and AI developers. The company also runs BEAM, a medical imaging exchange platform linking hospitals, healthcare systems, imaging centers, physicians, and patients. Based in Eden Prairie, Minnesota, OneMedNet has positioned itself as a source of regulatory-grade imaging Real World Data, which supports the rising need for high-quality, compliant datasets in AI model training and clinical research. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ONMD Stock Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, ONMD fell approximately 31%, declining from an adjusted closing price near $6.33 to roughly $4.39. The path was uneven, with the stock trading in the $6.50 to $7.00 range through much of September before breaking lower in late September and early October and settling near the $4.40 level. On a trailing-quarter basis, the decline is even more pronounced: shares traded near $7 in early-to-mid July and have since lost roughly 38% of their value. This reflects a sustained downtrend punctuated by brief rebounds, rather than a single-session shock. From what I see, the pattern aligns with broader market-structure influences rather than isolated events.
Factors Behind the Recent 30-Day Move
The most significant structural event of the period was a 1-for-10 reverse stock split, which took effect in late September 2026. Reverse splits of this kind are frequently implemented to lift a stock's nominal share price and satisfy exchange listing standards, but they can also introduce elevated volatility and, in some cases, renewed selling pressure as the post-split share count and float adjust. The company paired this corporate action with a steady cadence of commercial updates. In late September, OneMedNet announced a seven-figure multiyear agreement to deliver de-identified, multimodal longitudinal clinical Real World Data to a commercially scaled, AI-enabled precision medicine company. The company also signed Mediplexus as its eleventh channel partner, extending its Real World Data footprint into Korea and the Asia-Pacific region, and subsequently announced a channel partner agreement with a global pharmaceutical intelligence provider. Despite these announcements, which signaled commercial momentum, the shares continued to drift lower, suggesting that concerns around profitability, cash consumption, and the stock's thin liquidity outweighed the positive news flow in the near term. I reviewed the price action using Tickeron’s AI Trend Prediction Engine to confirm the trend.
Drivers of Performance Across the Full Quarter
The broader quarterly downtrend reflects a combination of fundamental and market-structure pressures. OneMedNet operates at an early commercial scale, with trailing twelve-month revenue in the low single-digit millions and a negative net income, meaning the business is still funding its expansion while managing cash burn. This profile tends to leave the stock sensitive to shifts in risk appetite and to any perceived financing or dilution overhang. The reverse stock split and the associated adjustments to share count added a further layer of uncertainty during the quarter. While the company's partnership activity demonstrates growing traction for its imaging Real World Data platform, the market has yet to reward that progress with sustained upward price momentum, and the stock's low trading volume has made its day-to-day moves more pronounced.
Key Variables to Monitor Going Forward
Looking ahead, the key variables for ONMD will be the pace of commercial execution and the company's path toward sustainable profitability. Investors are likely to monitor whether recent channel partnerships and data agreements convert into recurring revenue, as well as any updates on new provider-network additions and contract value. Quarterly earnings and cash-flow disclosures will remain important signals, given the company's ongoing losses and limited cash resources. Broader factors such as demand for Real World Data in AI-driven healthcare, regulatory developments affecting data privacy and compliance, and the stock's thin liquidity and low float are also worth watching. Because OneMedNet is a small-cap name with limited analyst coverage, price discovery can be volatile, and investors should weigh these risks carefully.
AI Trading Bots as Part of My Research Process
In my regular analysis workflow, I often review Tickeron's AI Trading Bots to compare automated strategies across different market conditions and timeframes. The selection includes bots with varying approaches and performance metrics, allowing me to identify those that align with specific objectives and risk levels. This has provided a useful perspective when evaluating how systematic tools might handle volatile names like ONMD.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ONMD's RSI Oscillator recovers from oversold territory
The RSI Oscillator for ONMD moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 18 of the 19 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ONMD as a result. In 46 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 29 of 58 cases over the following month. The odds of a continued upward trend are 50%.
Following a +4.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ONMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 18 of 48 cases where ONMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 38%.
ONMD moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ONMD crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-73.813) is very low in comparison to the industry average of (4.353). P/E Ratio (-2.576) is within average values for comparable stocks, (13.253). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement